ScreenPoint Medical, a Nijmegen-based Breast AI company focusing on breast cancer detection and risk assessment, has raised €11.9 million ($14 million) in new funding from existing investors, global software investor Insight Partners and Siemens Healthineers. It has also secured €1.7 million ($2 million) in non-dilutive research grants. With this funding,
Rahul Raj
ScreenPoint Medical, a Nijmegen-based Breast AI company focusing on breast cancer detection and risk assessment, has raised €11.9 million ($14 million) in new funding from existing investors, global software investor Insight Partners and Siemens Healthineers.
It has also secured €1.7 million ($2 million) in non-dilutive research grants. With this funding, the company aims to support product innovation, expand internationally, and pursue strategic initiatives to reinforce ScreenPoint Medical’s role in the future of breast cancer care.
“This investment endorses our strategy and our shared success. We are well-positioned to scale globally and accelerate the development of solutions that make care personal and powerful. Our goal is to support clinicians and women across the full continuum of breast cancer care,” said Pieter Kroese, CEO of ScreenPoint Medical.
ScreenPoint Medical was founded in 2014 by Professors Nico Karssemeijer and Sir Michael Brady, experts in quantitative breast imaging analysis and computer-aided detection. It was a spin-off from Radboud University Medical Centre in Nijmegen, the Netherlands.
It claims to build AI-powered technology for every stage of the breast imaging continuum, improving consistency, reducing uncertainty, enhancing the patient experience, and delivering on the promise of personalised, precision medicine.
Its flagship product is called Transpara. The Transpara Breast AI Suite is a growing hub for automated analysis of mammograms to improve early diagnosis of breast cancer. It is used to assist radiologists with the reading of 2D and 3D mammography exams. ScreenPoint Medical states that research indicates Transpara Detection can boost cancer detection by 29%, while also reducing workload and improving workflow efficiency.
The company reports that Transpara® Breast AI solutions are deployed in 30+ countries, with over 12 million mammograms processed to date. They are used by many of the world’s leading healthcare systems, screening programmes, universities, and imaging groups.
It also states that its solutions have been the subject of innovative new research this year. One notable study, the first randomised controlled trial (RCT) in breast cancer AI (MASAI), published its final results on the use of Transpara in The Lancet. The study found “consistently favourable outcomes compared to standard double reading,” including significant improvements in cancer detection and a reduction in workload.
“ScreenPoint Medical continues to lead and innovate in applying AI to breast imaging. The opportunity to create a greater level of personalised care is vast and clinically impactful at both a patient and population level. We are excited to support ScreenPoint Medical as it builds an integrated and comprehensive approach,” said Dr Robert Epstein, MD, FACR, Health Care Senior Advisor at Insight Partners.
